Trying to find a cure for cystic fibrosis: CFTR biomarkers asoutcomes

European Respiratory Journal

Volumn 42, Issue 4, 2013, Pages 1156-1157

  De Boeck, Kris ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ATALUREN; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; IVACAFTOR; LUMACAFTOR; MUCOLYTIC AGENT;

CYSTIC FIBROSIS; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFICACY; ENVIRONMENTAL STRESS; FORCED EXPIRATORY VOLUME; HUMAN; LETTER; LUNG FUNCTION; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN FUNCTION; QUALITY OF LIFE;

CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; HUMANS;

EID: 84886504903     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00029913     Document Type: Letter

References (7)

1. De Boeck K, Kent L, Davies J, et al. CFTR biomarkers: time for promotion to surrogate end-point? Eur Respir J 2013; 41: 203-216.
2. Durmowicz AG, Witzmann KA, Rosebraugh CJ, et al. Change in sweat chloride as a clinical end point in cystic fibrosis clinical trials: the ivacaftor experience. Chest 2013; 143: 14-18.
3. Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011; 365: 1663-1672.
4. Accurso FJ, Rowe SM, Clancy JP, et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 2010; 363: 1991-2003.
5. Clancy JP, Rowe SM, Accurso FJ, et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 2012; 67: 12-18.
6. Suri R, Metcalfe C, Wallis C, et al. Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respir Med 2007; 101: 254-260.
7. Brody AS, Sucharew H, Campbell JD, et al. Computed tomography correlates with pulmonary exacerbations in children with cystic fibrosis. Am J Respir Crit Care Med 2005; 172: 1128-1132.